Search Results - "BECKA, Michael"

Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban by Mueck, Wolfgang, Stampfuss, Jan, Kubitza, Dagmar, Becka, Michael

“…Rivaroxaban is an oral, direct Factor Xa inhibitor that targets free and clot-bound Factor Xa and Factor Xa in the prothrombinase complex. It is absorbed…”
Get full text

The effect of food on the absorption and pharmacokinetics of rivaroxaban by STAMPFUSS, Jan, KUBITZA, Dagmar, BECKA, Michael, MUECK, Wolfgang

“…Doses of 10 mg, 15 mg, and 20 mg of rivaroxaban are approved for the treatment and prevention of thromboembolic disorders in adult patients. In six Phase I…”
Get full text

The Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Rivaroxaban-An Oral, Direct Factor Xa Inhibitor by Kubitza, Dagmar, Becka, Michael, Roth, Angelika, Mueck, Wolfgang

“…A randomized, single‐blind, placebo‐controlled, parallel‐group study was conducted to assess the effect of age and gender on the pharmacokinetics and…”
Get full text

Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59-7939) in Healthy Subjects by Kubitza, Dagmar, Becka, Michael, Zuehlsdorf, Michael, Mueck, Wolfgang

“…Anticoagulants are often dose adjusted, or their use restricted, in patients with extremes of body weight. Rivaroxaban (BAY 59‐7939) is a novel, oral, direct…”
Get full text

Effects of the chymase inhibitor fulacimstat in diabetic kidney disease—results from the CADA DIA trial by Rossing, Peter, Strand, Jorma, Avogaro, Angelo, Becka, Michael, Kanefendt, Friederike, Otto, Christiane

“…Abstract Background The protease chymase generates multiple factors involved in tissue remodelling including angiotensin II (Ang II) and has been implicated in…”
Get full text

Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects by Kubitza, Dagmar, Becka, Michael, Roth, Angelika, Mueck, Wolfgang

“…ABSTRACT Objective: The aim of this study was to investigate the pharmacokinetics and pharmacodynamics of rivaroxaban - a novel, oral, direct Factor Xa (FXa)…”
Get full text

Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor by Kubitza, Dagmar, Becka, Michael, Mueck, Wolfgang, Halabi, Atef, Maatouk, Haidar, Klause, Norbert, Lufft, Volkmar, Wand, Dominic D., Philipp, Thomas, Bruck, Heike

“…WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Prior to the commencement of this study, it was already known that rivaroxaban is partially cleared via the kidneys…”
Get full text

Effect of Food, an Antacid, and the H2 Antagonist Ranitidine on the Absorption of BAY 59-7939 (Rivaroxaban), an Oral, Direct Factor Xa Inhibitor, in Healthy Subjects by Kubitza, Dagmar, Becka, Michael, Zuehlsdorf, Michael, Mueck, Wolfgang

“…To investigate the influence of food and administration of an antacid (aluminum‐magnesium hydroxide) or ranitidine on the absorption of BAY 59–7939…”
Get full text

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 : an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects by KUHITZA, Dagmar, BECKA, Michael, WENSING, Georg, VOITH, Barbara, ZUEHLSDORF, Michael

“…There is a clinical need for safe new oral anticoagulants. The safety, tolerability, pharmacodynamics, and pharmacokinetics of BAY 59-7939--a novel, oral,…”
Get full text

Serum markers detect the presence of liver fibrosis: A cohort study by Rosenberg, William M.C., Voelker, Michael, Thiel, Robert, Becka, Michael, Burt, Alastair, Schuppan, Detlef, Hubscher, Stefan, Roskams, Tania, Pinzani, Massimo, Arthur, Michael J.P.

“…Background & Aims: Histologic examination of a liver biopsy specimen is regarded as the reference standard for detecting liver fibrosis. Biopsy can be painful…”
Get full text

Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction—Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA MIA) 2 trial by Duengen, Hans-Dirk, Kim, Raymond J., Zahger, Doron, Orvin, Katia, Kornowski, Ran, Admon, Dan, Kettner, Jiri, Shimony, Avraham, Otto, Christiane, Becka, Michael, Kanefendt, Friederike, Romo, Andres Iniguez, Hasin, Tal, Ostadal, Petr, Rojas, Gonzalo Calvo, Senni, Michele, Podpera, Ivo, Linkova, Hana, Hajek, Petr, Bauersachs, Johann, Menck, Niels, Fuisting, Jan, Oumbe Tiam, Sadrack, Martinez Selles, Manuel, Miro Palau, Vicente, Roque, Mercedes, Ibanez, Borja, Arbel, Yaron, Nikolsky, Eugenia, Nodari, Savina, Silvio Marenzi, Gian Carlo, Achilli, Felice, Reimers, Bernhard

“…Adverse cardiac remodeling is a major risk factor for the development of post myocardial infarction (MI) heart failure (HF). This study investigates the…”
Get full text

Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study by Kubitza, Dagmar, Willmann, Stefan, Becka, Michael, Thelen, Kirstin, Young, Guy, Brandão, Leonardo R, Monagle, Paul, Male, Christoph, Chan, Anthony, Kennet, Gili, Martinelli, Ida, Saracco, Paola, Lensing, Anthonie W A

“…The EINSTEIN-Jr program will evaluate rivaroxaban for the treatment of venous thromboembolism (VTE) in children, targeting exposures similar to the 20 mg…”
Get full text

Topical administration of regorafenib eye drops: phase I dose‐escalation study in healthy volunteers by Zimmermann, Torsten, Höchel, Joachim, Becka, Michael, Boettger, Michael K., Rohde, Beate, Schug, Barbara, Kunert, Kathleen S., Donath, Frank

“…Aim Regorafenib is a multikinase inhibitor under investigation for use in neovascular age‐related macular degeneration. In this phase I study, regorafenib eye…”
Get full text

Randomized, Double-Blind, Crossover Study to Investigate the Effect of Rivaroxaban on QT-Interval Prolongation by Kubitza, Dagmar, Mueck, Wolfgang, Becka, Michael

“…Background: Rivaroxaban (BAY 59-7939) is a novel, oral, direct Factor Xa inhibitor in advanced clinical development for the prevention and treatment of…”
Get full text

Pharmacokinetics, Safety, and Tolerability of the Novel Chymase Inhibitor BAY 1142524 in Healthy Male Volunteers by Kanefendt, Friederike, Thuß, Uwe, Becka, Michael, Boxnick, Stefanie, Berse, Matthias, Schultz, Armin, Otto, Christiane

“…The orally available chymase inhibitor BAY 1142524 is currently being developed as a first‐in‐class treatment for left‐ventricular dysfunction after myocardial…”
Get full text

Investigation of Pharmacodynamic and Pharmacokinetic Interactions Between Rivaroxaban and Enoxaparin in Healthy Male Subjects by Kubitza, Dagmar, Becka, Michael, Schwers, Stephan, Voith, Barbara

“…Rivaroxaban, an oral, direct factor Xa inhibitor, is currently used in clinical practice for the prevention and treatment of thromboembolic disorders. This…”
Get full text

Effect of co-administration of rivaroxaban and clopidogrel on bleeding time, pharmacodynamics and pharmacokinetics: a phase I study by Kubitza, Dagmar, Becka, Michael, Mück, Wolfgang, Schwers, Stephan

“…Dual antiplatelet therapy with acetylsalicylic acid and a thienopyridine, such as clopidogrel, is effective for the secondary prevention of cardiovascular…”
Get full text

Co‐administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects by Mueck, Wolfgang, Kubitza, Dagmar, Becka, Michael

“…Aims The anticoagulant rivaroxaban is an oral, direct Factor Xa inhibitor for the management of thromboembolic disorders. Metabolism and excretion involve…”
Get full text

Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor by Kubitza, Dagmar, Roth, Angelika, Becka, Michael, Alatrach, Abir, Halabi, Atef, Hinrichsen, Holger, Mueck, Wolfgang

“…Aim This study investigated the effects of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban (10 mg), an oral,…”
Get full text

Effects of the Oral, Direct Factor Xa Inhibitor Rivaroxaban on Platelet‐Induced Thrombin Generation and Prothrombinase Activity1 by Graff, Jochen, Hentig, Nils, Misselwitz, Frank, Kubitza, Dagmar, Becka, Michael, Breddin, Hans‐Klaus, Harder, Sebastian

“…Rivaroxaban (BAY 59‐7939) is an oral, direct factor Xa inhibitor in advanced development. This study was undertaken to investigate its effects on thrombin…”
Get full text